Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Long-Term Investments (2021 - 2025)

Caribou Biosciences (CRBU) has disclosed Long-Term Investments for 5 consecutive years, with $3.5 million as the latest value for Q4 2025.

  • Quarterly Long-Term Investments fell 62.21% to $3.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.5 million through Dec 2025, down 62.21% year-over-year, with the annual reading at $3.5 million for FY2025, 62.21% down from the prior year.
  • Long-Term Investments for Q4 2025 was $3.5 million at Caribou Biosciences, down from $12.0 million in the prior quarter.
  • The five-year high for Long-Term Investments was $62.5 million in Q1 2023, with the low at $132000.0 in Q2 2025.
  • Average Long-Term Investments over 5 years is $21.6 million, with a median of $9.3 million recorded in 2025.
  • The sharpest move saw Long-Term Investments skyrocketed 714.66% in 2023, then crashed 99.74% in 2025.
  • Over 5 years, Long-Term Investments stood at $37.7 million in 2021, then plummeted by 79.57% to $7.7 million in 2022, then skyrocketed by 466.08% to $43.6 million in 2023, then tumbled by 78.71% to $9.3 million in 2024, then plummeted by 62.21% to $3.5 million in 2025.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $3.5 million, $12.0 million, and $132000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.